Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis

Trial Profile

Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Poloxamer 188 (Primary)
  • Indications Sickle cell anaemia; Veno-occlusive disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms EPIC
  • Sponsors Mast Therapeutics
  • Most Recent Events

    • 26 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 20 Sep 2016 Primary endpoint has not been met. (Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease.), as per Mast Therapeutics media release.
    • 20 Sep 2016 Top-line results published in Mast Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top